4276
We report five cases of carboplatin ( CBDCA ) hypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy .
 adverse effect: hypersensitivity, carboplatin; adverse effect: hypersensitivity, CBDCA; adverse effect: hypersensitivity, paclitaxel
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  hypersensitivity, carboplatin; hypersensitivity, CBDCA; hypersensitivity, paclitaxel 
Answer:
 adverse effect: hypersensitivity, carboplatin; adverse effect: hypersensitivity, CBDCA; adverse effect: hypersensitivity, paclitaxel